Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Inspire Medical Systems Sees Stock Surge with Upgraded Outlook

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 11/21/2025, 4:38 pm ET | 4 min
Inspire Medical Systems Sees Stock Surge with Upgraded Outlook Thumbnail

In this article Last trade Nov, 21 4:20 PM

  • INSP+7.93%
    INSP - NYSEInspire Medical Systems Inc.
    $89.87+6.60 (+7.93%)
    Volume:  1.66M
    Float:  28.39M
    $83.37Day Low/High$90.57

Inspire Medical Systems Inc.’s stocks have been trading up by 7.93 percent following improved market sentiment from positive clinical trial results.

Healthcare industry expert:

Analyst sentiment – positive

Inspire Medical Systems, Inc. (INSP) exhibits a robust market positioning within the healthcare sector, specifically in the medical equipment and supplies sub-industry. With a considerable gross margin of 84.5% and a current ratio of 6.1, Inspire stands resilient in terms of liquidity and operational efficiency. The enterprise value soars to $2.13 billion, supported by a stable capital structure with total debt to equity at 0.05, indicating minimal leverage. However, a thorough examination reveals a pretax profit margin of -2.5%, reflecting challenges in translating top-line growth into net profits, compounded by a high P/E ratio of 47.67 suggesting overvaluation risks.

The technical landscape for Inspire shows a remarkably bullish trend. The sequential price rise from $83 to $89.87, with a significant gap-up recorded on November 21st, suggests strong buyer interest and bullish momentum. The weekly candlestick analysis reveals ascendant price action backed by volume surges, indicating robust demand. A trading strategy would be to buy on slight pullbacks towards the $84-$85 support zone, setting a target around $90.87, where overhead resistance might be tested and watch for consolidation signals for taking profit whenever trading volumes systematically decline.

Recent developments indicate upward momentum driven by optimizing operational strategies, as evidenced by the uplifting of full-year EPS guidance and reported Q3 EPS exceeding expectations at 38 cents versus an anticipated loss. The company projects continued revenue growth tethering between $900M-$910M. However, Inspire Medical faces headwinds with litigation regarding its sleep apnea device, which could cap future price appreciation. Overall, while short-term prospects appear favorable, spearheaded by impressive EPS advancements and potentially significant tax benefits, market participants should remain agile given the lawsuit’s potential repercussions. Key support rests at $84, with resistance expected near $90—reaffirming a cautiously optimistic outlook.

Candlestick Chart

Weekly Update Nov 17 – Nov 21, 2025: On Friday, November 21, 2025 Inspire Medical Systems Inc. stock [NYSE: INSP] is trending up by 7.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In the recent quarter, Inspire Medical Systems showcased robust financial health with earnings reaching higher than market forecasts. Their adjusted earnings per share for Q3 came in at $0.38, surpassing the consensus which expected a loss. This impressive result was buttressed by a revenue figure of $224.5M, well above the predicted $220.39M. Such a performance underscores the company’s successful adaptation to the Inspire V system, demonstrating enhanced capabilities over older technologies.

The revised full-year 2025 earnings guidance now anticipates an EPS in the range of $0.90 to $1.00, a considerable uplift from previous estimates. This aligns with a solid revenue projection between $900M and $910M, marking growth of approximately 12-13% compared to last year. Crucially, these figures point to effective operational strategies and investor confidence in the firm’s outlook. The reported income tax benefit due to adjustments in deferred tax assets further strengthens their financial position. As of November 21, the stock closed at $89.87, having opened at $83.57 just days prior, indicating a bullish investor response to the new information.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

In this article (YTD Performance)

  • INSP-55.08%
    INSP - NYSEInspire Medical Systems Inc.
    $89.87+6.60 (+7.93%)
    Volume:  1.66M
    Float:  28.39M
    $83.37Day Low/High$90.57

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM
notification icon
Subscribe to receive notifications